Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Redhill Biophrma ADR (RDHL)

Redhill Biophrma ADR (RDHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease PR Newswire - Thu Apr 30, 6:00AM CDT

RHB-204 1  is a next-generation optimized formulation of RedHill's oral RHB-104 2 , designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking...

RDHL : 0.9200 (-0.87%)
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights PR Newswire - Mon Apr 27, 7:00AM CDT

2025 was a year of tenacity, strategic transactions and building traction for RedHill

RDHL : 0.9200 (-0.87%)
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 PR Newswire - Wed Apr 22, 7:00AM CDT

New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib [1] as potential...

RDHL : 0.9200 (-0.87%)
CPIX : 5.53 (+2.22%)
Joint U.S. Commercialization of RedHill's Talicia® Commences PR Newswire - Wed Feb 25, 6:00AM CST

The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and...

RDHL : 0.9200 (-0.87%)
CPIX : 5.53 (+2.22%)
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects PR Newswire - Mon Jan 5, 6:00AM CST

RHB-102 1  is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute...

RDHL : 0.9200 (-0.87%)
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells PR Newswire - Mon Dec 15, 2025

Resistance to venetoclax (Venclexta ®  and Venclyxto ® , Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge,...

RDHL : 0.9200 (-0.87%)
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement PR Newswire - Mon Dec 1, 2025

TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that...

RDHL : 0.9200 (-0.87%)
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement PR Newswire - Tue Nov 4, 2025

RALEIGH, N.C. and TEL-AVIV, Israel , Nov. 4, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL ) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced...

RDHL : 0.9200 (-0.87%)
RedHill Biopharma Receives Nasdaq Staff Determination Notification PR Newswire - Wed Oct 22, 2025

On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for continued...

RDHL : 0.9200 (-0.87%)
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO PR Newswire - Mon Oct 20, 2025

 Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy

RDHL : 0.9200 (-0.87%)
CPIX : 5.53 (+2.22%)

Barchart Exclusives

Berkshire Hathaway Gave Up on This Underperforming Dividend Stock, But It May Be Time for You to Buy the Dip Barchart - 1 hour ago
Berkshire Hathaway dumped its stake in Domino's Pizza in Q1. The stock has a healthy dividend yield of 2.6% and is trading at reasonable valuations though. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.